Indeed, recent use of new SGLT1 inhibitors was shown to reduce blood glucose levels and improve metabolic parameters in T2D patients without serious gastrointestinal side effects [8]. The gene discussed is SLC5A1; the disease is type 2 diabetes mellitus.